liu.seSök publikationer i DiVA
Ändra sökning
Avgränsa sökresultatet
12 51 - 77 av 77
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Träffar per sida
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
Markera
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 51.
    Mellqvist, Ulf-Henrik
    et al.
    Sahlgrens University Hospital.
    Westin, Jan
    Rigshosp, Copenhagen, Denmark .
    Hjertner, Oyvind
    St Olavs Hospital.
    Lenhoff, Stig
    Lund University Hospital.
    Laane, Edward
    North Estonian Regional Hospital.
    Remes, Kari
    Turku University.
    Steingrimsdottir, Hlif
    Landspitali University Hospital.
    Abildgaard, Niels
    Odense University Hospital.
    Ahlberg, Lucia
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Carlsson, Kristina
    University of North Norway.
    Forsberg, Karin
    Norrlands University Hospital.
    Gedde-Dahl, Tobias
    University Hospital, Rikshosp, Oslo, Norway .
    Gregersen, Henrik
    Aalborg Hospital.
    Gruber, Astrid
    Karolinska Institute.
    Guldbrandsen, Nina
    Ullevaal University Hospital.
    Haukas, Einar
    Stavanger University Hospital.
    Linder, Olle
    Orebro University Hospital.
    Nahi, Hareth
    Karolinska University Hospital.
    Nesthus, Ingerid
    Haukeland Hospital.
    Toffner-Clausen, Nilsaage
    Amtsygehuset Herlev, Copenhagen, Denmark .
    Silvennoinen, Raija
    Tampere University Hospital.
    Frost Andersen, Niels
    Aarhus University Hospital.
    Turesson, Ingemar
    Malmö University Hospital.
    Waage, Anders
    St Olavs University Hospital.
    Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial in BLOOD, vol 114, issue 22, pp 221-2212009Ingår i: BLOOD, American Society of Hematology , 2009, Vol. 114, nr 22, s. 221-221Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

  • 52. Merup, M
    et al.
    Lazarevic, V
    Nahi, H
    Andreasson, B
    Malm, Claes
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Nilsson, L
    Brune, M
    LeBlanc, K
    Kutti, J
    Birgegard, G
    Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens2006Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 135, nr 3, s. 367-373Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.

  • 53.
    Mohty, M.
    et al.
    Service d'Hématologie Clinique, CHU Hôtel Dieu, Université de Nantes, Nantes, France, Service d'Hématologie Clinique, CHU Hôtel-Dieu, Université de Nantes, Place Alexis Ricordeau, F-44093 Nantes, France.
    Labopin, M.
    European Group for Blood and Marrow Transplantation (EBMT), Hopital Saint-Antoine, Université de Paris 6, Pierre et Marie Curie, Paris, France.
    Tabrizzi, R.
    Centre Hospitalo-Universitaire de Bordeaux, Hôpital Haut-Leveque, Pessac, France.
    Theorin, Niklas
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Fauser, A.A.
    Klinik fuer Knochenmarktransplantation und Haematologie/Onkologie, Idar-Oberstein, Germany.
    Rambaldi, A.
    Ospedale Bergamo, Divisione di Ematologia, Bergamo, Italy.
    Maertens, J.
    University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium.
    Slavin, S.
    Hadassah University Hospital, Department of Bone Marrow Transplantation, Jerusalem, Israel.
    Majolino, I.
    Ospedale S. Camillo-Forlanini, Dept. of Hematology and BMT, Rome, Italy.
    Nagler, A.
    Tel-Aviv University, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
    Blaise, D.
    Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France.
    Rocha, V.
    European Group for Blood and Marrow Transplantation (EBMT), Hopital Saint-Antoine, Université de Paris 6, Pierre et Marie Curie, Paris, France, Department of Hematology, Hopital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France.
    Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation2008Ingår i: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 93, nr 2, s. 303-306Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52±9%, 42±10%, and 18±7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively). In multivariate analysis, disease status (CR1 vs. advanced, p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation. ©2008 Ferrata Storti Foundation.

  • 54.
    Mohty, Mohamad
    et al.
    CHU Nantes.
    Labopin, Myriam
    Hop St Antoine.
    Basara, Nadezda
    University of Leipzig.
    Cornelissen, Jan J
    Erasmus MC Daniel Den Hoed, Rotterdam, Netherlands .
    Tabrizi, Reza
    CHU Bordeaux.
    Malm, Claes
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Perez Simon, Jose Antonio
    Hospital University Salamanca.
    Nagler, Arnon
    Chaim Sheba Medical Centre.
    Kroger, Nicolaus
    University of Hamburg Hospital.
    Rio, Bernard
    Hop Hotel Dieu.
    Martino, Rodrigo
    Hospital Santa Creu and Sant Pau.
    Eder, Matthias
    Hannover Medical School.
    Bilger, Karin
    Hop Hautepierre, Strasbourg, France .
    W Bunjes, Donald W
    University of Ulm Klinikum.
    Socie, Gerard
    Institute J Paoli I Calmettes.
    Polge, Emmanuelle
    EBMT Paris Off.
    Rocha, Vanderson
    Hop St Louis.
    Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) in BLOOD, vol 114, issue 22, pp 270-2702009Ingår i: BLOOD, American Society of Hematology , 2009, Vol. 114, nr 22, s. 270-270Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

  • 55.
    Mohty, Mohamad
    et al.
    CHU Nantes.
    Labopin, Myriam
    EBMT Paris.
    Milpied, Noel-Jean
    Erasmus MC Daniel Den Hoed.
    Blaise, Didier
    Institute J Paoli I Calmettes.
    Petersen, Eefke
    University Medical Centre Utrecht.
    Theorin, Niklas
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Goker, Hakan
    Hacettepe University.
    Socie, Gerard
    Hop St Louis.
    Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)2008Ingår i: American Society of Hematology Meeting: in: Blood Volume 112, Issue 11, 2008, Vol. 112, nr 11, s. 134-135Konferensbidrag (Refereegranskat)
  • 56.
    Mustjoki, Satu
    et al.
    University of Helsinki.
    Richter, Johan
    Lund University Hospital.
    Barbany, Gisela
    Karolinska University Hospital.
    Dybedal, Ingunn
    University of Oslo.
    Fioretos, Thoas
    Lund University Hospital.
    Gedde Dahl, Tobias
    University of Oslo.
    Gjertsen, Bjorn T
    Haukeland Hospital.
    Hovland, Randi
    Haukeland Hospital.
    Jalkanen, Sari
    University of Helsinki.
    Josefsen, Dag
    Norwegian Radium Hospital.
    Koskenvesa, Perttu
    University Helsinki.
    Lassen, Carin
    Lund University Hospital.
    Latvala, Kirsi
    University of Helsinki.
    Majeed, Waleed
    Stavanger University Hospital.
    Malm, Claes
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Markevarn, Berit
    Norrland University Hospital.
    Moshfegh, Ali
    Karolinska University Hospital.
    Ohm, Lotta
    Karolinska University Hospital.
    Olofsson, Tor
    Lund University Hospital.
    Olsson Stromberg, Ulla
    University Uppsala Hospital.
    Rapakko, Katrin
    Oulu University Hospital.
    Remes, Kari
    Turku University.
    Stentoft, Jesper
    Arhus University Hospital.
    Stenke, Leif
    Karolinska University Hospital.
    Suominen, Merja
    Kanta Hame Cent Hospital.
    Thunberg, Sara
    Karolinska University Hospital.
    Weiss Bjerrum, Ole
    Rigshosp, Copenhagen.
    Simonsson, Bengt
    University Uppsala Hospital.
    Porkka, Kimmo
    University Helsinki.
    Hjorth Hansen, Henrik
    St Olavs Hospital.
    The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study2010Ingår i: BLOOD vol 116, issue 21 (ISSN 0006-4971), American Society of Hematology , 2010, Vol. 116, nr 21, s. 291-292Konferensbidrag (Refereegranskat)
  • 57.
    Nagler, A
    et al.
    Chaim Sheba Medical Centre.
    Labopin, M
    University of Paris 06.
    Shimoni, A
    Chaim Sheba Medical Centre.
    Mufti, G
    GKT School of Medicine.
    Cornelissen, J J
    Erasmus MC, Netherlands .
    Blaise, D
    Institute J Paoli I Calmettes.
    Janssen, J J W M
    Vrije University Amsterdam.
    Milpied, N
    CHU Bordeaux.
    Vindelov, L
    Rigshospital, Copenhagen.
    Petersen, E
    University Medical Centre, Utrecht.
    Gribben, J
    St Bartholomews and Royal London Hospital.
    Bacigalupo, A
    Osped San Martino Genova.
    Malm, Claes
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Niederwieser, D
    University Hospital Leipzig.
    Socie, G
    Hopital St Louis, Paris.
    Arnold, R
    Charite, Campus Virchow Klinikum.
    Brown, P
    St James Hospital.
    Goker, H
    Hacettepe University.
    Mohty, M
    Hematol Clinic, Nantes.
    Rocha, V
    Department Hematology, Paris.
    Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT in BONE MARROW TRANSPLANTATION, vol 45, issue , pp S21-S222010Ingår i: BONE MARROW TRANSPLANTATION, Nature Publishing Group , 2010, Vol. 45, s. S21-S22Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

  • 58. Olsson-Strömberg, U
    et al.
    Höglund, M
    Björkholm, M
    Braide, I
    Carlson, K
    Gahrton, G
    Grimfors, G
    Hast, R
    Lerner, r
    Linder, O
    Ljungman, P
    Löfvenberg, E
    Malm, Claes
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Nilsson, PG
    Paul, c
    Rodjer, s
    Stenke, L
    Tidefeldt, U
    Turesson, I
    Uden, AM
    Wahlin, A
    Vilén, L
    Winqvist, I
    Zettervall, O
    Öberg, G
    Simonsson, B
    Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy+ G-CSF in patients with chronic myelogenous leukemia in first chronic phase2006Ingår i: Leukemia and Lymphoma, ISSN 1042-8194, E-ISSN 1029-2403, Vol. 47, nr 9, s. 1768-1773Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-1999 12 centers included 37 patients <56 years. All patients received 6 months' IFN, stopping at median 36 (1-290) days prior to the mobilization chemotherapy. All received one cycle of daunorubicin 50 mg/m2 and 1 hour infusion on days 1-3, and cytarabine (ara-C) 200 mg/m2 24 hours' i.v. infusion on days 1-7 (DA) followed by G-CSF 526 μg s.c. once daily from day 8 after the start of chemotherapy. Leukaphereses were initiated when the number of CD 34+ cells was >5/μ blood. Patients mobilizing poorly could receive a 4-day cycle of chemotherapy with mitoxantrone 12 mg/m2/day and 1 hour i.v infusion, etoposide 100 mg/m2/day and 1 hour i.v. infusion and ara-C 1 g/m2/twice a day with 2 hours' i.v infusion (MEA) or a second DA, followed by G-CSF 526 μg s.c once daily from day 8 after the start of chemotherapy. Twenty-seven patients received one cycle of chemotherapy and G-CSF, whereas 10 were mobilized twice. Twenty-three patients (62%) were successfully (MNC >3.5 × 108/kg, CFU-GM >1.0 × 104/kg, CD34+ cells >2.0 × 106/kg and no Ph+ cells in the apheresis product) [n = 16] or partially successfully (as defined above but 1-34% Ph+ cells in the apheresis product) [n = 7] mobilized. There was no mortality during the mobilization procedure. Twenty-one/23 patients subsequently underwent auto-SCT. The time with PMN <0.5 × 109/l was 10 (range 7-49) and with platelets <20 × 109/l was also 10 (2-173) days. There was no transplant related mortality. The estimated 5-year overall survival after auto-SCT was 68% (95% CI 47-90%), with a median follow-up time of 5.2 years. We conclude that in a significant proportion of patients with CML in CP 1, intensive chemotherapy combined with G-CSF mobilizes Ph - BSC sufficient for use in auto-SCT.

  • 59. Olsson-Strömberg, Ulla
    et al.
    Simonsson, Bengt
    Ahlgren, Tomas
    Björkholm, Magnus
    Carlsson, Karin
    Gahrton, Gösta
    Hast, Robert
    Löfvenberg, Eva
    Linder, Olle
    Ljungman, Per
    Malm, Claes
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Paul, Christer
    Rödjer, Stig
    Turesson, Ingemar
    Udén, Ann-Mari
    Wahlin, Anders
    Killander, Andreas
    Wadman, Bengt
    Westin, Jan
    Vikrot, Olle
    Zettervall, Olle
    Öberg, Gunnar
    Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival2004Ingår i: The Hematology Journal, ISSN 1466-4860, E-ISSN 1476-5632, Vol. 5, nr 6, s. 462-466Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Introduction: Whether busulphan-treated patients develop blastic transformation earlier than hydroxyurea treated has been a controversial issue. In a randomised prospective study, we examined the busulphan versus hydroxyurea influence on time to blast crisis and on survival. When we opened our study in 1984, the clinical benefit of allogeneic bone marrow transplantation (BMT) was not well known, to follow up the long-time outcome of this treatment was therefore of great interest. Materials and methods: Previously untreated CML patients were randomly started on either hydroxyurea (30 mg/kg/day) or busulphan (0.1 mg/kg/day). The end points of the study were overall survival and time to blast crisis. A total of 26 patients subsequently underwent BMT. Results: A total of 179 patients were randomised, 90 to hydroxyurea, and 89 to busulphan treatment. There was no significant difference in survival between hydroxyurea- and busulphan-treated patients (P = 0.46), median survival was 3.5 and 3.2 years, respectively. In all, 85 of the patients were subsequently diagnosed with blast crisis, 41 in the busulphan and 44 in the hydroxyurea group. There was no significant difference between the two groups (P=0.91). The 26 patients who were allotransplanted survived significantly longer than those who were not transplanted (P=0.0001). The 5-year-survival rates were 50 and 22% and the 10-year-survival rates were 46 and 2%, respectively. The median survival was 4.7 years for the transplanted and 3.3 years for the nontransplanted patients. Conclusion: We did not find any difference between hydroxyurea and busulphan treatment, either in overall survival or in blast crisis-free survival, transplanted patients survived significantly longer than nontransplanted patients. © 2004 The European Hematology Association All rights reserved.

  • 60. Panagopoulos, Ioannis
    et al.
    Fioretos, Thoas
    Isaksson, Margareth
    Mitelman, Felix
    Johansson, Bertil
    Theorin, Niklas
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Hematologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Hematologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    RT-PCR analysis of acute myeloid leukemia with t(8,16)(p11,p13): Identification of a novel MOZ/CBP transcript and absence of CBP/MOZ expression [1]2002Ingår i: Genes, Chromosomes and Cancer, ISSN 1045-2257, E-ISSN 1098-2264, Vol. 35, nr 4, s. 372-374Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    [No abstract available]

  • 61.
    Rosengren, S
    et al.
    Uppsala University Hospital.
    Ahlberg, Lucia
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Forsberg, K
    Umeå University Hospital.
    Lenhoff, S
    Lund University Hospital.
    Mellqvist, U
    Sahlgrenska University Hospital.
    Nahi, H
    Karolinska University Hospital.
    Carlson, K
    OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AL-AMYLOIDOSIS IN SWEDEN in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol 95, issue , pp 393-3932010Ingår i: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Pensiero Scientifico / Ferrata Storti Foundation , 2010, Vol. 95, s. 393-393Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

  • 62.
    Simonsson, B
    et al.
    University Uppsala Hospital.
    Gedde-Dahl, M
    National Hospital Norway.
    Markevarn, M
    University Uppsala Hospital.
    Remes, P
    Turku University Hospital.
    Stentoft, R
    University Uppsala Hospital.
    Almqvist, S
    Vaasa Cent Hospital.
    Bjoreman, T
    University Uppsala Hospital.
    Flogegard, V
    Falun Cent Hospital.
    Hallman, U
    Cent Finland Cent Hospital.
    Koskenveesa, L
    University of Helsinki.
    Lindblom, A
    Malmö University Hospital.
    Malm, Claes
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Mustjoki, S
    University of Helsinki.
    Myhr-Eriksson, K
    Luleå Central Hospital.
    Rasanen, A
    Kymenlaakso Central Hospital.
    Sinisalo, M
    Tampere University Hospital.
    Sippola, R
    Lapland Cent Hospital.
    Sjalander, A
    Sundsvall Cent Hospital.
    Stromberg, U
    University Uppsala Hospital.
    Weiss Bjerrum, O
    Rigshospital, Copenhagen.
    Ehrencrona, H
    Uppsala University.
    Gruber, F
    Akershus University Hospital.
    Kairisto, V
    Reginal Oncology Centre, Uppsala.
    Sandin, F
    Reginal Oncology Centre, Uppsala.
    Nagler, A
    Chaim Sheba Medical Centre.
    Lanng Nielsen, J
    Aarhus University Hospital.
    Hjorth-Hansen, H
    St Olavs Hospital.
    Porkka, K
    University Helsinki.
    MAJOR MOLECULAR RESPONSE RATE AT ONE YEAR IS HIGHER IF PEGYLATED INTERFERON ALPHA-2B IS ADDED TO IMATINIB IN NON-HR CHRONIC MYELOID LEUKEMIA PATIENTS IN IMATINIB INDUCED COMPLETE HEMATOLOGICAL REMISSION in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol 95, issue , pp 457-4572010Ingår i: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Pensiero Scientifico / Ferrata Storti Foundation , 2010, Vol. 95, s. 457-457Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

  • 63.
    Simonsson, Bengt
    et al.
    Uppsala University Hospital.
    Gedde-Dahl, Tobias
    University of Oslo, Rikshospital.
    Markevarn, Berit
    Umeå University Hospital.
    Remes, Kari
    Turku University.
    Stentoft, Jesper
    Aarhus University Hospital.
    Almqvist, Anders
    Vaasa Central Hospital.
    Bjoreman, Mats
    Örebro University Hospital.
    Flogegard, Max
    Falun Central Hospital.
    Hallman, Heikki
    Central Finland Hospital.
    Koskenvesa, Perttu
    University of Helsinki.
    Lindblom, Anders
    Malmö University Hospital.
    Malm, Claes
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Mustjoki, Satu
    University of Helsinki.
    Myhr-Eriksson, Kristina
    Luleå Central Hospital.
    Rasanen, Anu
    Kymenlaakso Central Hospital.
    Sinisalo, Marjatta
    Tampere University Hospital.
    Sippola, Risto
    Lapland Central Hospital.
    Sjalander, Anders
    Sunsvall Centtal Hospital.
    Stromberg, Ulla
    Uppsala University Hospital.
    Weiss Bjerrum, Ole
    Rigshospital, Copenhagen.
    Ehrencrona, Hans
    Uppsala University Hospital.
    Gruber, Franz
    Akershus University Hospital.
    Kairisto, Veli
    Turku University.
    Olsson, Karin
    Uppsala University Hospital.
    Nagler, Arnon
    Chaim Sheba Medical Centre.
    Lanng Nielsen, Johan
    Aarhus University Hospital.
    Hjorth-Hansen, Henrik
    St Olavs Hospital.
    Porkka, Kimmo
    University of Helsinki.
    A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy. in BLOOD, vol 114, issue 22, pp 1269-12702009Ingår i: BLOOD, American Society of Hematology , 2009, Vol. 114, nr 22, s. 1269-1270Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

  • 64. Simonsson, Bengt
    et al.
    Öberg, Gunnar
    Björeman, Mats
    Björkholm, Magnus
    Carneskog, Jan
    Karlsson, Karin
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Gahrton, Gösta
    Grimfors, Gunnar
    Hast, Robert
    Karle, Hans
    Linder, Olle
    Ljungman, Per
    Nielsen, Johan L
    Nilsson, Jonas
    Löfvenberg, Eva
    Malm, Claes
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Olsson, Karin
    Olsson-Strömberg, Ulla
    Paul, Christer
    Stenke, Leif
    Stentoft, Jesper
    Turesson, Ingemar
    Udén, Ann-Marie
    Wahlin, Anders
    Vilén, Lars
    Weis-Bjerrum, Ole
    Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up2005Ingår i: Acta Haematologica, ISSN 0001-5792, E-ISSN 1421-9662, Vol. 113, nr 3, s. 155-162Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    In the present study we combined interferon (IFN) and hydroxyurea (HU) treatment, intensive chemotherapy and autologous stem cell transplantation (SCT) in newly diagnosed chronic myelogenous leukemia patients aged below 56 years, not eligible for allogeneic SCT. Patients who had an HLA-identical sibling donor and no contraindication went for an allogeneic SCT (related donor, RD). After diagnosis, patients not allotransplanted received HU and IFN to keep WBC and platelet counts low. After 6 months patients with Ph-positive cells still present in the bone marrow received 1-3 courses of intensive chemotherapy. Those who became Ph-negative after IFN + HU or after 1-3 chemotherapy courses underwent autologous SCT. Some patients with poor cytogenetic response were allotransplanted with an unrelated donor (URD). IFN + HU reduced the percentage of Ph-positive metaphases in 56% of patients, and 1 patient became Ph-negative. After one or two intensive cytotherapies 86 and 88% had a Ph reduction, and 34 and 40% became Ph-negative, respectively. In patients receiving a third intensive chemotherapy 92% achieved a Ph reduction and 8% became Ph-negative. The median survival after auto-SCT (n = 46) was 7.5 years. The chance of remaining Ph-negative for up to 10 years after autologous SCT was around 20%. The overall survival for allo-SCT RD (n = 91) and URD (n = 28) was almost the same, i.e. ≈ 60% at 10 years. The median survival for all 251 patients registered was 8 years (historical controls 3.5 years). The role of the treatment schedule presented in the imatinib era is discussed. Copyright © 2005 S. Karger AG.

  • 65.
    Skogsberg, A.
    et al.
    Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Tobin, G.
    Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Krober, A.
    Kröber, A., Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Kienle, D.
    Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Thunberg, U.
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Aleskog, A.
    Åleskog, A., Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.
    Karlsson, K.
    Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Laurell, A.
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Merup, M.
    Department of Medicine, Karolinska University Hospital, Huddinge, Sweden.
    Vilpo, J.
    Department of Clinical Chemistry, Tampere University Hospital, Tampere, Finland.
    Sundstrom, C.
    Sundström, C., Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Roos, G.
    Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
    Jernberg-Wiklund, H.
    Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Dohner, H.
    Döhner, H., Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Nilsson, K.
    Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
    Stilgenbauer, S.
    Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Rosenquist, R.
    Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
    The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia2006Ingår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 20, nr 1, s. 77-81Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    The G(-248)A polymorphism in the promoter region of the Bax gene was recently associated with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL), the latter particularly in treated patients. To investigate this further, we analyzed 463 CLL patients regarding the presence or absence of the G(-248)A polymorphism and correlated with overall survival, treatment status and known prognostic factors, for example, Binet stage, VH mutation status and genomic aberrations. In this material, similar allele and genotype frequencies of the Bax polymorphism were demonstrated in CLL patients and controls (n=207), where 19 and 21% carried this polymorphism, respectively, and no skewed distribution of the polymorphism was evident between different Binet stages and VH mutated and unmutated CLLs. Furthermore, no difference in overall survival was shown between patients displaying the G(-248)A polymorphism or not (median survival 85 and 102 months, respectively, P=0.21), and the polymorphism did not influence outcome specifically in treated CLL. Neither did the polymorphism affect outcome in prognostic subsets defined by VH mutation status or genomic aberrations. In conclusion, the pathogenic role and clinical impact of the Bax polymorphism is limited in CLL. © 2006 Nature Publishing Group All rights reserved.

  • 66. Storlazzi, Clelia T
    et al.
    Fioretos, Thoas
    Paulsson, Kajsa
    Strömbeck, Bodil
    Lassen, Carin
    Ahlgren, Tomas
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Mitelman, Felix
    Rocchi, Mariano
    Johansson, Bertil
    Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies2004Ingår i: Human Molecular Genetics, ISSN 0964-6906, E-ISSN 1460-2083, Vol. 13, nr 14, s. 1479-1485Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Double minutes (dmin), the cytogenetic hallmark of genomic amplification, are found in ∼1% of karyotypically abnormal acute myelold leukemias (AML) and myelodysplastic syndromes (MDS). The MYC gene at 8q24 has been reported to be amplified in the majority of the cases, and generally it has been assumed that MYC is the target gene. However, only a few studies have focused on the extent of the amplicon or on the expression patterns of the amplified genes. We have studied six cases (five AML and one MDS) with MYC-containing dmin. Detailed fluorescence in situ hybridization analyses identified a common 4.3 Mb amplicon, with clustered proximal and distal breakpoints, harboring eight known genes (C8FW, NSE2, POU5FLC20, MYC, PVT1, AK093424, MGC27434 and MLZE). The corresponding region was deleted in one of the chromosome 8 homologues in five of the six cases, suggesting that the dmin originated through extra replication (or loop-formation)-excision-amplification. Northern blot analysis revealed that MYC was not overexpressed. Instead, the C8FW gene, encoding a phosphoprotein regulated by mitogenic pathways, displayed increased expression. These results exclude MYC as the target gene and indicate that overexpression of C8FW may be the functionally important consequence of 8q24 amplicons in AML and MDS. © Oxford University Press 2004, all rights reserved.

  • 67.
    Söderholm, Johan D
    et al.
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Kirurgi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Kirurgiska kliniken i Östergötland med verksamhet i Linköping, Norrköping och Motala.
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Sjödahl, Rune
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Kirurgi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Kirurgiska kliniken i Östergötland med verksamhet i Linköping, Norrköping och Motala.
    Long-term endoscopic remission in a case of Crohn's disease after autologous bone marrow transplantation.2000Ingår i: Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012, Vol. 118, nr 4, s. 4212-Konferensbidrag (Övrigt vetenskapligt)
  • 68.
    Söderholm, Johan D
    et al.
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Kirurgi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Kirurgiska kliniken i Östergötland med verksamhet i Linköping, Norrköping och Motala.
    Malm, Claes
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Hematologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Hematologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Sjödahl, Rune
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Kirurgi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Kirurgiska kliniken i Östergötland med verksamhet i Linköping, Norrköping och Motala.
    Long-term endoscopic remission of Crohn disease after autologous stem cell transplantation for acute myeloid leukaemia2002Ingår i: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 37, nr 5, s. 613-616Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    A favourable course of Crohn disease has been observed after allogeneic bone marrow transplantation, and there is now mounting evidence that autologous stem cell may be an effective treatment for severe autoimmune diseases. Here, we present the first long-term endoscopic follow-up of a patient with Crohn disease undergoing autologous stem cell transplantation for haematological disease. A 54-year-old woman developed Crohn disease and was submitted to ileocaecal resection. Four months after surgery, the patient contracted acute myeloid leukaemia. She was initially treated with chemotherapy, and subsequently underwent autologous stem cell transplantation. Following transplantation, the patient has remained in clinical remission regarding both diseases, without anti-inflammatory medication. She has undergone ileo-colonoscopy with normal findings at 1, 2, 3 and 5 years after transplantation. This case suggests that autologous stem cell transplantation can change not only the clinical course, but also the natural history of intestinal inflammation in Crohn disease. This has pathophysiological as well as therapeutic implications.

  • 69. Tidefelt, U
    et al.
    Liliemark, J
    Gruber, A
    Sundman-Engberg, B
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Hematologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Stenke, L
    Elmhorn-Rosenborg, A
    Möllgård, L
    Lehman, S
    Xu, D
    Covelli, A
    Gustavsson, B
    Paul, C
    Liliemark, E
    P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of Deunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.2000Ingår i: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 18, s. 1837-1844Artikel i tidskrift (Refereegranskat)
  • 70. Tobin, G
    et al.
    Thunberg, U
    Johnson, A
    Eriksson, I
    Soderberg, O
    Karlsson, K
    Merup, M
    Enblad, G
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Vilpo, J
    Sundstrom, C
    Roos, G
    Rosenquist, R
    V(a)3-21 gene utilizing chronic lymphocytic leukemias display restricted V lambda 2-14 gene usage and homologous CDR3s.2002Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 100, nr 11, s. 362-Konferensbidrag (Övrigt vetenskapligt)
  • 71. Tobin, G
    et al.
    Thunberg, U
    Johnson, A
    Eriksson, I
    Soderberg, O
    Karlsson, Karin
    Linköpings universitet, Institutionen för biomedicin och kirurgi, Hematologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken.
    Merup, M
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Vilpo, J
    Enblad, G
    Sundstrom, C
    Roos, G
    Rosenquist, R
    Chronic lymphocytic leukemias utilizing the V(H)3-21 gene display highly restricted V(lambda)2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope2003Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 101, nr 12, s. 4952-4957Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    The immunoglobulin variable heavy chain (IgV(H)) gene mutation status is an important prognostic factor in chronic lymphocytic leukemia (CLL), since cases with mutated V-H genes show significantly longer survival than unmutated cases. Recently, we reported a preferential use of the V(H)3-21 gene in mutated CLL and showed that mutated V(H)3-21 cases had an inferior overall survival compared with other mutated CLL. In order to further characterize this subset, we performed VH gene analysis in 265 CLL cases and identified 31 V(H)3-21 cases (11.7%), 21 cases had mutated and 10 cases unmutated VH genes. Regardless Of VH gene mutation status, a poor overall survival was found in the VH3-21 cases with a median survival of 83 months. These survival data confirm that V(H)3-21 cases do not fit into the general prognostic grouping of mutated and unmutated CLL. A large fraction Of V(H)3-21 cases also demonstrated unique features with shorter lengths of the third complementarity determining region (CDR3) and CDR3s with highly homologous amino acid sequences. Furthermore, the V(H)3-21 cases showed a striking dominance of X light chain expression, and analysis of the Iglambda gene rearrangements revealed highly restricted use of the Vlambda2-14/J(lambda)3 genes in the majority of cases. Taken together, our new findings strengthen the suggestion that V(H)3-21-using cases comprise a new CLL entity, irrespective Of VH gene mutation status, and implicate that a common antigen epitope, perhaps of pathogenic significance, is recognized by the highly homologous V(H)3-21/V(lambda)2-14 Ig molecules expressed in individual tumors. (Blood. 2003,101:4952-4957).

  • 72. Tobin, Gerard
    et al.
    Thunberg, Ulf
    Karlsson, Karin
    Murray, Fiona
    Laurell, Anna
    Willander, Kerstin
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi.
    Enblad, Gunilla
    Merup, Mats
    Vilpo, Juhani
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Sundström, Christer
    Söderberg, Ola
    Roos, Göran
    Rosenquist, Richard
    Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia2004Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 104, s. 2879-2885Artikel i tidskrift (Refereegranskat)
  • 73. Waage, A
    et al.
    Romstad, L
    Brenne, AT
    Gimsing, P
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Turesson, I
    Borset, M
    Sundan, A
    Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma.2002Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 100, nr 11, s. 5082-Konferensbidrag (Övrigt vetenskapligt)
  • 74.
    Waage, Anders
    et al.
    NTNU.
    Gimsing, Peter
    Rigshospital, Copenhagen.
    Fayers, Peter
    Norwegian University Science and Technology.
    Abildgaard, Niels
    Odense University Hospital.
    Ahlberg, Lucia
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Bjorkstrand, Bo
    Karolinska University Hospital.
    Carlson, Kristina
    University Uppsala Hospital.
    Dahl, Inger Marie
    University Tromso Hospital.
    Forsberg, Karin
    Norrland University Hospital.
    Gulbrandsen, Nina
    University of Oslo.
    Haukas, Einar
    Stavanger University Hospital.
    Hjertner, Oyvind
    Norwegian University Science and Technology.
    Hjorth, Martin
    Lidkoping Hospital.
    Karlsson, Torbjorn
    Capio Sankt Gorans Hospital.
    Meldgaard Knudsen, Lene
    Herlev Hospital.
    Lanng Nielsen, Johan
    Aarhus University Hospital.
    Linder, Olle
    Orebro University Hospital.
    Mellqvist, Ulf-Henrik
    Sahlgrens University Hospital.
    Nesthus, Ingerid
    Haukeland Hospital.
    Rolke, Jurgen
    Kristiansand Hospital.
    Strandberg, Maria
    Sundsvalls Hospital.
    Wisloff, Finn
    University of Oslo.
    Juliusson, Gunnar
    Lund University Hospital.
    Turesson, Ingemar
    Malmo University Hospital.
    Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma2010Ingår i: BLOOD, ISSN 0006-4971, Vol. 116, nr 9, s. 1405-1412Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P andlt; .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, non-neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at www.clinicaltrials.gov as #NCT00218855.

  • 75. Waage, Anders
    et al.
    Gimsing, Peter
    Juliusson, Gunnar
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för biomedicin och kirurgi, Onkologi. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Turesson, Ingemar
    Gulbrandsen, Nina
    Eriksson, Tommy
    Hjorth, Martin
    Lanng Nielsen, Johan
    Lenhoff, Stig
    Westin, Jan
    Wislöff, Finn
    Early response predicts thalidomide efficiency in patients with advanced multiple myeloma2004Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 125, nr 2, s. 149-155Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Sixty-five patients who were primary or secondary refractory to melphalan/ prednisone or other type of chemotherapy, or relapsed within 6 months after high dose chemotherapy with stem cell support, were given thalidomide at a dose of 200 mg/d escalating to 800 mg. The patients were followed for a median of 2 years and 22 weeks. Response was evaluated according to M-protein reduction combined with improvement of haemoglobin (Hb) concentration, renal function and pain. Altogether, 14% of patients had a minor response, 14% partial response and 6% complete response. Median survival was 12 months and 29% were alive at last contact. Decline of M protein started early and a minimum 25% reduction of M protein was detected in 14 of 20 responders (70%) after 3 weeks, and in 20 of 22 responders (91%) after 5 weeks of treatment. Reduction of M protein continued for 3 months and further decline was observed in only four patients. The Hb concentration showed a different time course, with a significant increase after 3 months and further increases continued for up to 12 months. Blood concentration levels of thalidomide from 40 patients were used to evaluate the pharmacokinetics of the drug. Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively. We found no relationship between thalidomide concentration and effect after 12 weeks.

  • 76.
    Willander, Kerstin
    et al.
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    Ungerbäck, Jonas
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Cellbiologi. Linköpings universitet, Hälsouniversitetet.
    Karlsson, Karin
    Department of Hematology, Lund University Hospital, Lund, Sweden.
    Fredrikson, Mats
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Yrkes- och miljömedicin. Linköpings universitet, Hälsouniversitetet.
    Söderkvist, Peter
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Cellbiologi. Linköpings universitet, Hälsouniversitetet.
    Linderholm, Mats
    Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia2010Ingår i: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 85, nr 3, s. 251-256Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    BACKGROUND: The single nucleotide polymorphism SNP309 with a change from T to G in the promoter region of the MDM2 gene is shown to increase the MDM2 protein levels and attenuate the p53 levels and associates with disease progression in several tumors. OBJECTIVE: In this study, the role of the polymorphism was investigated with regard to the clinical outcome in B-cell chronic lymphocytic leukemia (B-CLL). PATIENTS: A total of 210 patients with B-CLL were followed for up to 19 yr. RESULTS: The overall survival (OS) of patients with at least one G-allele was significantly shorter when compared with those with two T-alleles (P = 0.024) with a more pronounced difference in patients below the median age. Age at onset of B-CLL was similar irrespective of MDM2 status. The presence of a G-allele in combination with TP53 mutations or unmutated IgVH gene status resulted in an additive risk of death. CONCLUSION: In this report, with a high proportion of B-CLL patients with an advanced Binet stage and with an unmutated IgVH gene, MDM2 SNP309 was found to be independently associated with OS. The survival difference was more pronounced in younger patients.

  • 77.
    Zervas, K.
    et al.
    Theagene Anticancer Hospital.
    Katodritou, E.
    Theagen Cancer Centre.
    Delforge, M.
    University Hospital Leuven.
    de Samblanx, H.
    ZNA Middelheim.
    Sargin, D.
    Istanbul University.
    Hulin, C.
    University Nancy Brabois.
    Ahlberg, Lucia
    Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Hematologiska kliniken US.
    de la Rubia, J.
    Hospital La Fe.
    Abdulkadyrov, K.
    Russian Science Research Institute.
    Ganguly, R.
    Johnson & Johnson Pharmaceutical.
    Diels, J.
    Johnson & Johnson Pharmaceutical.
    Dhawan, R.
    Johnson & Johnson Pharmaceutical.
    PATIENT RESPONSE TO BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: INTERIM RESULTS FROM AN OBSERVATIONAL STUDY2009Ingår i: in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol 94, 2009, Vol. 94, s. 1591-Konferensbidrag (Refereegranskat)
    Abstract [en]

    n/a

12 51 - 77 av 77
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf